| 0.827 | 0.004 | 0.827 | Amyloid beta aggregation inhibitor | | |
| 0.814 | 0.009 | 0.814 | Caspase 9 stimulant | | |
| 0.767 | 0.005 | 0.767 | Aldehyde oxidase inhibitor | | |
| 0.754 | 0.004 | 0.754 | Free radical scavenger | | |
| 0.737 | 0.005 | 0.737 | Antioxidant | | |
| 0.706 | 0.004 | 0.706 | Superoxide dismutase inhibitor | | |
| 0.721 | 0.027 | 0.721 | Apoptosis agonist | | |
| 0.663 | 0.003 | 0.663 | Peroxidase inhibitor | | |
| 0.614 | 0.006 | 0.614 | GABA C receptor rho-3 antagonist | | |
| 0.586 | 0.004 | 0.586 | NOS3 expression enhancer | | |
| 0.57 | 0.015 | 0.57 | 12-Lipoxygenase inhibitor | | |
| 0.571 | 0.035 | 0.571 | Transcription factor NF kappa B inhibitor | | |
| 0.536 | 0.006 | 0.536 | Tubulin antagonist | | |
| 0.529 | 0.003 | 0.529 | Cystathionine beta-synthase inhibitor | | |
| 0.534 | 0.016 | 0.534 | Caspase 3 stimulant | | |
| 0.535 | 0.022 | 0.535 | 5 Hydroxytryptamine release stimulant | | |
| 0.515 | 0.004 | 0.515 | Estrogen antagonist | | |
| 0.509 | 0.005 | 0.509 | Amylase inhibitor | | |
| 0.523 | 0.022 | 0.523 | Histamine release inhibitor | | |
| 0.517 | 0.027 | 0.517 | 5 Hydroxytryptamine release inhibitor | | |
| 0.495 | 0.008 | 0.495 | Monophenol monooxygenase inhibitor | | |
| 0.503 | 0.018 | 0.503 | Lipoxygenase inhibitor | | |
| 0.486 | 0.004 | 0.486 | Estrogen receptor beta antagonist | | |
| 0.478 | 0.004 | 0.478 | Tyrosine 3 hydroxylase inhibitor | | |
| 0.473 | 0.005 | 0.473 | Amyloid beta precursor protein antagonist | | |
| 0.465 | 0.005 | 0.465 | Chelator | | |
| 0.493 | 0.034 | 0.493 | Cholesterol antagonist | | |
| 0.464 | 0.005 | 0.464 | 5-Lipoxygenase inhibitor | | |
| 0.465 | 0.006 | 0.465 | Lipid peroxidase inhibitor | | |
| 0.46 | 0.02 | 0.46 | Antiamyloidogenic | | |
| 0.454 | 0.017 | 0.454 | Antimitotic | | |
| 0.517 | 0.081 | 0.517 | Antiinflammatory | | |
| 0.444 | 0.009 | 0.444 | Melanin inhibitor | | |
| 0.445 | 0.014 | 0.445 | Pyruvate kinase inhibitor | | |
| 0.45 | 0.021 | 0.45 | Hypoglycemic | | |
| 0.442 | 0.013 | 0.442 | Calcium channel activator | | |
| 0.475 | 0.046 | 0.475 | 15-Lipoxygenase inhibitor | | |
| 0.432 | 0.004 | 0.432 | Carbonic anhydrase III inhibitor | | |
| 0.454 | 0.027 | 0.454 | Apoptosis antagonist | | |
| 0.418 | 0.004 | 0.418 | M18 aspartyl aminopeptidase inhibitor | | |
| 0.42 | 0.011 | 0.42 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.427 | 0.022 | 0.427 | Nitric oxide antagonist | | |
| 0.405 | 0.004 | 0.405 | Histone deacetylase SIRT1 stimulant | | |
| 0.405 | 0.004 | 0.405 | Histone deacetylase stimulant | | |
| 0.443 | 0.043 | 0.443 | Vasodilator, peripheral | | |
| 0.404 | 0.004 | 0.404 | Estrogen agonist | | |
| 0.398 | 0.004 | 0.398 | Beta tubulin antagonist | | |
| 0.401 | 0.009 | 0.401 | Alpha-N-acetylglucosaminidase inhibitor | | |
| 0.395 | 0.004 | 0.395 | HIV-1 integrase (3'-Processing) inhibitor | | |
| 0.393 | 0.004 | 0.393 | Carbonic anhydrase VI inhibitor | | |
| 0.42 | 0.034 | 0.42 | Aryl hydrocarbon receptor agonist | | |
| 0.388 | 0.003 | 0.388 | Keratolytic | | |
| 0.391 | 0.008 | 0.391 | Cyclooxygenase 1 inhibitor | | |
| 0.388 | 0.004 | 0.388 | Carbonic anhydrase XV inhibitor | | |
| 0.388 | 0.009 | 0.388 | Protein kinase stimulant | | |
| 0.435 | 0.059 | 0.435 | Calcium channel L-type activator | | |
| 0.377 | 0.003 | 0.377 | Phenylalanine 4-hydroxylase inhibitor | | |
| 0.375 | 0.004 | 0.375 | Alcohol oxidase inhibitor | | |
| 0.405 | 0.037 | 0.405 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | | |
| 0.459 | 0.093 | 0.459 | Alpha-glucosidase inhibitor | | |
| 0.399 | 0.035 | 0.399 | Vasodilator, coronary | | |
| 0.362 | 0.004 | 0.362 | Histidine decarboxylase inhibitor | | |
| 0.377 | 0.025 | 0.377 | Transcription factor STAT inhibitor | | |
| 0.353 | 0.003 | 0.353 | Creatine kinase inhibitor | | |
| 0.373 | 0.023 | 0.373 | Interleukin agonist | | |
| 0.367 | 0.027 | 0.367 | Transcription factor STAT3 inhibitor | | |
| 0.387 | 0.05 | 0.387 | Streptokinase A inhibitor | | |
| 0.35 | 0.014 | 0.35 | Interferon gamma antagonist | | |
| 0.333 | 0.004 | 0.333 | Estrogen receptor beta agonist | | |
| 0.357 | 0.029 | 0.357 | Sigma receptor agonist | | |
| 0.331 | 0.004 | 0.331 | HIV-1 integrase (Strand Transfer) inhibitor | | |
| 0.34 | 0.014 | 0.34 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | | |
| 0.401 | 0.076 | 0.401 | Antibacterial | | |
| 0.33 | 0.006 | 0.33 | Nitric-oxide synthase stimulant | | |
| 0.331 | 0.007 | 0.331 | Succinate dehydrogenase inhibitor | | |
| 0.347 | 0.026 | 0.347 | Cyclic AMP phosphodiesterase inhibitor | | |
| 0.335 | 0.016 | 0.335 | MAO inhibitor | | |
| 0.332 | 0.015 | 0.332 | Phospholipase C inhibitor | | |
| 0.321 | 0.004 | 0.321 | Alpha tubulin antagonist | | |
| 0.356 | 0.043 | 0.356 | Hypoxia-inducible factor 1 alpha inhibitor | | |
| 0.325 | 0.013 | 0.325 | Neurotrophic factor enhancer | | |
| 0.34 | 0.035 | 0.34 | Angiogenesis stimulant | | |
| 0.345 | 0.042 | 0.345 | DNA damaging | | |
| 0.308 | 0.006 | 0.308 | Beta glucuronidase inhibitor | | |
| 0.34 | 0.038 | 0.34 | Insulysin inhibitor | | |
| 0.307 | 0.009 | 0.307 | GABA C receptor agonist | | |
| 0.303 | 0.007 | 0.303 | Xanthine oxidase inhibitor | | |
| 0.301 | 0.006 | 0.301 | Carbonic anhydrase XIII inhibitor | | |
| 0.29 | 0.004 | 0.29 | Estrogen receptor alpha agonist | | |
| 0.291 | 0.005 | 0.291 | Porphobilinogen synthase inhibitor | | |
| 0.328 | 0.042 | 0.328 | Interleukin antagonist | | |
| 0.297 | 0.015 | 0.297 | MAO A inhibitor | | |
| 0.286 | 0.008 | 0.286 | Breast cancer-resistant protein inhibitor | | |
| 0.345 | 0.066 | 0.345 | Antithrombotic | | |
| 0.281 | 0.005 | 0.281 | NAD(P)H dehydrogenase (quinone) inhibitor | | |
| 0.28 | 0.005 | 0.28 | Macrophage migration inhibitory factor inhibitor | | |
| 0.303 | 0.028 | 0.303 | P-glycoprotein inhibitor | | |
| 0.287 | 0.014 | 0.287 | MAO B inhibitor | | |
| 0.286 | 0.013 | 0.286 | Cholesterol synthesis inhibitor | | |
| 0.284 | 0.013 | 0.284 | Aldehyde dehydrogenase inhibitor | | |
| 0.296 | 0.028 | 0.296 | DNA methyltransferase I inhibitor | | |
| 0.289 | 0.021 | 0.289 | Protein-tyrosine phosphatase inhibitor | | |
| 0.284 | 0.017 | 0.284 | Heat shock protein 90 alpha antagonist | | |
| 0.272 | 0.006 | 0.272 | Toll-Like receptor 2 antagonist | | |
| 0.323 | 0.059 | 0.323 | Sodium/bile acid cotransporter inhibitor | | |
| 0.295 | 0.034 | 0.295 | Anesthetic general | | |
| 0.291 | 0.03 | 0.291 | Dual specificity phosphatase inhibitor | | |
| 0.263 | 0.003 | 0.263 | DOPA decarboxylase inhibitor | | |
| 0.273 | 0.014 | 0.273 | DNA polymerase I inhibitor | | |
| 0.292 | 0.033 | 0.292 | RNA-directed DNA polymerase inhibitor | | |
| 0.32 | 0.063 | 0.32 | Spasmolytic | | |
| 0.333 | 0.078 | 0.333 | Angiogenesis inhibitor | | |
| 0.264 | 0.009 | 0.264 | Farnesoid X receptor antagonist | | |
| 0.266 | 0.011 | 0.266 | Interleukin 4 antagonist | | |
| 0.259 | 0.005 | 0.259 | Estrogen receptor alpha antagonist | | |
| 0.287 | 0.033 | 0.287 | Hepatoprotectant | | |
| 0.275 | 0.022 | 0.275 | Cyclooxygenase inhibitor | | |
| 0.256 | 0.004 | 0.256 | Glutamate decarboxylase inhibitor | | |
| 0.375 | 0.125 | 0.375 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | | |
| 0.249 | 0.005 | 0.249 | TRPA1 agonist | | |
| 0.276 | 0.033 | 0.276 | Dual specificity phosphatase 3 inhibitor | | |
| 0.277 | 0.036 | 0.277 | DNA methylase inhibitor | | |
| 0.245 | 0.005 | 0.245 | Thioredoxin inhibitor | | |
| 0.265 | 0.027 | 0.265 | Insulin sensitizer | | |
| 0.252 | 0.017 | 0.252 | Hexokinase inhibitor | | |
| 0.249 | 0.013 | 0.249 | UDP-glucose 4-epimerase inhibitor | | |
| 0.326 | 0.091 | 0.326 | Prostaglandin dehydrogenase inhibitor | | |
| 0.246 | 0.012 | 0.246 | GABA C receptor rho-2 antagonist | | |
| 0.245 | 0.014 | 0.245 | Ferrochelatase inhibitor | | |
| 0.25 | 0.021 | 0.25 | Heat shock protein 90 antagonist | | |
| 0.28 | 0.051 | 0.28 | DNA synthesis inhibitor | | |
| 0.244 | 0.018 | 0.244 | Protein-tyrosine phosphatase 1B inhibitor | | |
| 0.266 | 0.041 | 0.266 | Neuropeptide Y2 antagonist | | |
| 0.248 | 0.025 | 0.248 | Topoisomerase II inhibitor | | |
| 0.232 | 0.01 | 0.232 | CF transmembrane conductance regulator agonist | | |
| 0.255 | 0.034 | 0.255 | Mcl-1 antagonist | | |
| 0.271 | 0.053 | 0.271 | 5 Hydroxytryptamine 1E antagonist | | |
| 0.288 | 0.073 | 0.288 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | | |
| 0.237 | 0.023 | 0.237 | Alkaline phosphatase inhibitor | | |
| 0.226 | 0.012 | 0.226 | Topoisomerase II alpha inhibitor | | |
| 0.222 | 0.008 | 0.222 | HIV-1 integrase (Overall Integration) inhibitor | | |
| 0.221 | 0.007 | 0.221 | Adenylate cyclase stimulant | | |
| 0.254 | 0.041 | 0.254 | Non-steroidal antiinflammatory agent | | |
| 0.225 | 0.015 | 0.225 | Interleukin 1b antagonist | | |
| 0.234 | 0.024 | 0.234 | Neurotensin receptor agonist | | |
| 0.222 | 0.013 | 0.222 | Cyclooxygenase 3 inhibitor | | |
| 0.214 | 0.007 | 0.214 | Prolactin inhibitor | | |
| 0.23 | 0.023 | 0.23 | Interleukin 1 antagonist | | |
| 0.269 | 0.066 | 0.269 | Tumour necrosis factor alpha release inhibitor | | |
| 0.252 | 0.05 | 0.252 | Peptidyltransferase inhibitor | | |
| 0.249 | 0.05 | 0.249 | Platelet adhesion inhibitor | | |
| 0.232 | 0.034 | 0.232 | Histone acetyltransferase inhibitor | | |
| 0.202 | 0.005 | 0.202 | Carbonic anhydrase VB inhibitor | | |
| 0.201 | 0.006 | 0.201 | Heat shock protein 70 antagonist | | |
| 0.205 | 0.012 | 0.205 | GABA C receptor antagonist | | |
| 0.214 | 0.021 | 0.214 | Arachidonic acid antagonist | | |
| 0.217 | 0.024 | 0.217 | Cell wall synthesis inhibitor | | |
| 0.257 | 0.065 | 0.257 | Vasodilator | | |
| 0.215 | 0.023 | 0.215 | Catenin beta inhibitor | | |
| 0.198 | 0.007 | 0.198 | Carbonic anhydrase V inhibitor | | |
| 0.213 | 0.024 | 0.213 | Mannose-6-phosphate isomerase inhibitor | | |
| 0.201 | 0.012 | 0.201 | Vanilloid 1 agonist | | |
| 0.215 | 0.027 | 0.215 | ATPase inhibitor | | |
| 0.226 | 0.039 | 0.226 | Tumour necrosis factor antagonist | | |
| 0.202 | 0.015 | 0.202 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | | |
| 0.219 | 0.039 | 0.219 | Cytidine deaminase inhibitor | | |
| 0.218 | 0.038 | 0.218 | 5 Hydroxytryptamine 3E antagonist | | |
| 0.248 | 0.068 | 0.248 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | | |
| 0.199 | 0.02 | 0.199 | Microtubule formation inhibitor | | |
| 0.189 | 0.012 | 0.189 | Triose-phosphate isomerase inhibitor | | |
| 0.245 | 0.069 | 0.245 | Calpain inhibitor | | |
| 0.238 | 0.063 | 0.238 | Psychostimulant | | |
| 0.178 | 0.007 | 0.178 | Myeloperoxidase inhibitor | | |
| 0.177 | 0.007 | 0.177 | Carbonic anhydrase VA inhibitor | | |
| 0.199 | 0.031 | 0.199 | Cyclooxygenase 2 inhibitor | | |
| 0.186 | 0.019 | 0.186 | Sphingosine 1-phosphate receptor 5 antagonist | | |
| 0.177 | 0.01 | 0.177 | Toll-Like receptor 4 antagonist | | |
| 0.176 | 0.009 | 0.176 | Ca2+-transporting ATPase inhibitor | | |
| 0.18 | 0.012 | 0.18 | NADH dehydrogenase inhibitor | | |
| 0.171 | 0.005 | 0.171 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | | |
| 0.179 | 0.012 | 0.179 | GABA C receptor rho-1 antagonist | | |
| 0.183 | 0.017 | 0.183 | Photosensitizer | | |
| 0.169 | 0.005 | 0.169 | Purinergic P2X1 antagonist | | |
| 0.178 | 0.015 | 0.178 | Alcohol dehydrogenase inhibitor | | |
| 0.169 | 0.006 | 0.169 | HIV-1 integrase inhibitor | | |
| 0.203 | 0.041 | 0.203 | Phospholipase A2 inhibitor | | |
| 0.236 | 0.074 | 0.236 | Hypolipemic | | |
| 0.181 | 0.019 | 0.181 | Potassium channel (Ca-activated) activator | | |
| 0.197 | 0.035 | 0.197 | NADPH oxidase inhibitor | | |
| 0.313 | 0.151 | 0.313 | Cyclophilin D inhibitor | | |
| 0.165 | 0.005 | 0.165 | Elastase 1 inhibitor | | |
| 0.17 | 0.013 | 0.17 | Transcription factor STAT6 inhibitor | | |
| 0.175 | 0.018 | 0.175 | Sphingosine 1-phosphate receptor 2 antagonist | | |
| 0.174 | 0.017 | 0.174 | Sphingosine 1-phosphate receptor 4 antagonist | | |
| 0.185 | 0.028 | 0.185 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | | |
| 0.176 | 0.02 | 0.176 | Mediator release inhibitor | | |
| 0.166 | 0.011 | 0.166 | Anabolic | | |
| 0.161 | 0.006 | 0.161 | GABA aminotransferase inhibitor | | |
| 0.162 | 0.008 | 0.162 | Ornithine decarboxylase inhibitor | | |
| 0.261 | 0.107 | 0.261 | Interleukin 2 agonist | | |
| 0.173 | 0.021 | 0.173 | Mucolytic | | |
| 0.177 | 0.026 | 0.177 | Expectorant | | |
| 0.179 | 0.03 | 0.179 | Cathepsin H inhibitor | | |
| 0.246 | 0.098 | 0.246 | Immunostimulant | | |
| 0.152 | 0.004 | 0.152 | Estrogen-related receptor beta agonist | | |
| 0.158 | 0.01 | 0.158 | Aldose reductase inhibitor | | |
| 0.168 | 0.021 | 0.168 | Papain-like protease (SARS coronavirus) inhibitor | | |
| 0.16 | 0.014 | 0.16 | NMDA 2 receptor antagonist | | |
| 0.229 | 0.082 | 0.229 | Dyrk kinase inhibitor | | |
| 0.15 | 0.005 | 0.15 | D-Ala-D-Ala ligase inhibitor | | |
| 0.154 | 0.011 | 0.154 | Interleukin 12 antagonist | | |
| 0.298 | 0.155 | 0.298 | Transcription factor inhibitor | | |
| 0.216 | 0.074 | 0.216 | ErbB-1 antagonist | | |
| 0.164 | 0.023 | 0.164 | Catalase inhibitor | | |
| 0.148 | 0.007 | 0.148 | Xanthine dehydrogenase inhibitor | | |
| 0.142 | 0.003 | 0.142 | Dopamine D5 agonist | | |
| 0.149 | 0.009 | 0.149 | TRPA1 antagonist | | |
| 0.161 | 0.022 | 0.161 | AMP-activated protein kinase stimulant | | |
| 0.204 | 0.067 | 0.204 | I kappa B kinase epsilon inhibitor | | |
| 0.141 | 0.005 | 0.141 | Aryl hydrocarbon receptor antagonist | | |
| 0.144 | 0.01 | 0.144 | Thioredoxin reductase inhibitor | | |
| 0.137 | 0.003 | 0.137 | Heme oxygenase stimulant | | |
| 0.14 | 0.007 | 0.14 | Estradiol 17 beta-dehydrogenase inhibitor | | |
| 0.137 | 0.004 | 0.137 | Estradiol 17 beta-dehydrogenase 2 inhibitor | | |
| 0.268 | 0.136 | 0.268 | Calpain 2 inhibitor | | |
| 0.134 | 0.003 | 0.134 | CYP24 inhibitor | | |
| 0.155 | 0.025 | 0.155 | Adenylate kinase inhibitor | | |
| 0.14 | 0.012 | 0.14 | Leukotriene antagonist | | |
| 0.139 | 0.011 | 0.139 | Biliverdin reductase inhibitor | | |
| 0.147 | 0.019 | 0.147 | Phosphofructokinase-1 inhibitor | | |
| 0.152 | 0.024 | 0.152 | NMDA receptor antagonist | | |
| 0.164 | 0.037 | 0.164 | Adenylate cyclase inhibitor | | |
| 0.164 | 0.036 | 0.164 | Topoisomerase I inhibitor | | |
| 0.141 | 0.014 | 0.141 | Aromatase inhibitor | | |
| 0.23 | 0.105 | 0.23 | Gastrin inhibitor | | |
| 0.148 | 0.024 | 0.148 | Urease inhibitor | | |
| 0.128 | 0.006 | 0.128 | GABA B receptor agonist | | |
| 0.133 | 0.012 | 0.133 | Bile acid receptor antagonist | | |
| 0.125 | 0.004 | 0.125 | Squalene epoxidase inhibitor | | |
| 0.291 | 0.17 | 0.291 | DNA polymerase beta inhibitor | | |
| 0.125 | 0.004 | 0.125 | Catechol O-methyltransferase inhibitor | | |
| 0.137 | 0.017 | 0.137 | Lanosterol 14 alpha demethylase inhibitor | | |
| 0.151 | 0.031 | 0.151 | DNA repair enzyme inhibitor | | |
| 0.123 | 0.005 | 0.123 | Leukotriene D4 antagonist | | |
| 0.123 | 0.004 | 0.123 | Glucose-6-phosphate translocase inhibitor | | |
| 0.259 | 0.141 | 0.259 | Immunosuppressant | | |
| 0.137 | 0.019 | 0.137 | Inducible nitric-oxide synthase inhibitor | | |
| 0.166 | 0.048 | 0.166 | Bone formation stimulant | | |
| 0.157 | 0.041 | 0.157 | Antibacterial (Helicobacter pylori) | | |
| 0.131 | 0.016 | 0.131 | CDC25A inhibitor | | |
| 0.152 | 0.037 | 0.152 | Death-associated protein kinase 1 inhibitor | | |
| 0.158 | 0.043 | 0.158 | Alkylator | | |
| 0.129 | 0.015 | 0.129 | Vanilloid agonist | | |
| 0.142 | 0.028 | 0.142 | Sphingomyelinase inhibitor | | |
| 0.125 | 0.011 | 0.125 | Glycine receptor agonist | | |
| 0.147 | 0.033 | 0.147 | Protein kinase C gamma inhibitor | | |
| 0.121 | 0.007 | 0.121 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | | |
| 0.16 | 0.049 | 0.16 | Acetylcholinesterase inhibitor | | |
| 0.118 | 0.007 | 0.118 | Carbonic anhydrase XIV inhibitor | | |
| 0.282 | 0.172 | 0.282 | DNA directed DNA polymerase inhibitor | | |
| 0.147 | 0.039 | 0.147 | Aminopeptidase B inhibitor | | |
| 0.149 | 0.041 | 0.149 | Beta amyloid protein antagonist | | |
| 0.112 | 0.004 | 0.112 | NMDA 2D receptor antagonist | | |
| 0.159 | 0.052 | 0.159 | Neurotrophic factor | | |
| 0.135 | 0.029 | 0.135 | Protein kinase C delta inhibitor | | |
| 0.112 | 0.006 | 0.112 | MAP kinase kinase 7 inhibitor | | |
| 0.119 | 0.016 | 0.119 | Granulocyte macrophage colony stimulating factor agonist | | |
| 0.107 | 0.004 | 0.107 | Dihydroorotate oxidase inhibitor | | |
| 0.119 | 0.017 | 0.119 | Leukotriene synthesis inhibitor | | |
| 0.138 | 0.036 | 0.138 | Bronchodilator | | |
| 0.123 | 0.022 | 0.123 | Phosphodiesterase 6D inhibitor | | |
| 0.132 | 0.031 | 0.132 | Uric acid excretion stimulant | | |
| 0.113 | 0.012 | 0.113 | Maillard reaction inhibitor | | |
| 0.129 | 0.029 | 0.129 | Androgen antagonist | | |
| 0.151 | 0.053 | 0.151 | Nav1.6 sodium channel blocker | | |
| 0.15 | 0.052 | 0.15 | Pregnane X receptor agonist | | |
| 0.119 | 0.023 | 0.119 | Glutamate dehydrogenase inhibitor | | |
| 0.119 | 0.023 | 0.119 | Glutathione S-transferase inhibitor | | |
| 0.129 | 0.035 | 0.129 | Acetylcholine release stimulant | | |
| 0.104 | 0.009 | 0.104 | Glutamate (mGluR group III) agonist | | |
| 0.1 | 0.006 | 0.1 | Transcription factor RelA inhibitor | | |
| 0.113 | 0.019 | 0.113 | Sphingosine 1-phosphate receptor 4 agonist | | |
| 0.098 | 0.004 | 0.098 | Adenylate cyclase 1 inhibitor | | |
| 0.135 | 0.041 | 0.135 | Caspase 3 inhibitor | | |
| 0.122 | 0.031 | 0.122 | Protein kinase C zeta inhibitor | | |
| 0.104 | 0.014 | 0.104 | Potassium channel (ATP-sensitive) blocker | | |
| 0.098 | 0.008 | 0.098 | Sphingosine kinase 2 inhibitor | | |
| 0.134 | 0.045 | 0.134 | 5 Hydroxytryptamine 3A agonist | | |
| 0.098 | 0.01 | 0.098 | Carbonic anhydrase VII inhibitor | | |
| 0.097 | 0.011 | 0.097 | Enoyl-[acyl-carrier-protein] reductase inhibitor | | |
| 0.165 | 0.079 | 0.165 | 3C-like protease (Human coronavirus) inhibitor | | |
| 0.145 | 0.059 | 0.145 | Toll-Like receptor antagonist | | |
| 0.088 | 0.003 | 0.088 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | | |
| 0.09 | 0.005 | 0.09 | Leukotriene C antagonist | | |
| 0.138 | 0.055 | 0.138 | Anesthetic local | | |
| 0.103 | 0.02 | 0.103 | Carbamoyl phosphate synthetase inhibitor | | |
| 0.092 | 0.01 | 0.092 | Aconitate hydratase inhibitor | | |
| 0.111 | 0.029 | 0.111 | Glutamate release inhibitor | | |
| 0.099 | 0.017 | 0.099 | Neuraminidase (influenza) inhibitor | | |
| 0.147 | 0.065 | 0.147 | Histone deacetylase SIRT1 inhibitor | | |
| 0.115 | 0.034 | 0.115 | ABCA1 expression enhancer | | |
| 0.106 | 0.025 | 0.106 | Aminopeptidase I inhibitor | | |
| 0.087 | 0.007 | 0.087 | Estrogen-related receptor alpha antagonist | | |
| 0.106 | 0.026 | 0.106 | Na+ K+ transporting ATPase inhibitor | | |
| 0.1 | 0.021 | 0.1 | CC chemokine 5 receptor agonist | | |
| 0.129 | 0.05 | 0.129 | Interleukin 8 antagonist | | |
| 0.095 | 0.017 | 0.095 | NMDA 2B receptor antagonist | | |
| 0.118 | 0.039 | 0.118 | Nitric-oxide synthase inhibitor | | |
| 0.095 | 0.018 | 0.095 | CDC25B inhibitor | | |
| 0.088 | 0.013 | 0.088 | Leukotriene B4 antagonist | | |
| 0.103 | 0.028 | 0.103 | Nicotinic alpha4beta2 receptor antagonist | | |
| 0.089 | 0.014 | 0.089 | Fatty acid synthase inhibitor | | |
| 0.093 | 0.018 | 0.093 | NMDA 2C receptor antagonist | | |
| 0.114 | 0.041 | 0.114 | Electrolyte absorption antagonist | | |
| 0.125 | 0.052 | 0.125 | Polo-like kinase-4 inhibitor | | |
| 0.078 | 0.005 | 0.078 | Dopamine beta hydroxylase inhibitor | | |
| 0.146 | 0.073 | 0.146 | Hemostatic | | |
| 0.085 | 0.013 | 0.085 | Sphingosine kinase inhibitor | | |
| 0.089 | 0.018 | 0.089 | Glutamate (mGluR7) antagonist | | |
| 0.145 | 0.073 | 0.145 | MAP kinase kinase 4 inhibitor | | |
| 0.129 | 0.059 | 0.129 | Proteasome inhibitor | | |
| 0.095 | 0.026 | 0.095 | Potassium channel large-conductance Ca-activated activator | | |
| 0.119 | 0.05 | 0.119 | Multidrug resistance-associated protein 1 inhibitor | | |
| 0.089 | 0.02 | 0.089 | 5 Hydroxytryptamine 2A agonist | | |
| 0.088 | 0.019 | 0.088 | Beta 3 adrenoreceptor antagonist | | |
| 0.121 | 0.053 | 0.121 | Falcipain 3 inhibitor | | |
| 0.072 | 0.004 | 0.072 | Estrogen-related receptor beta antagonist | | |
| 0.085 | 0.018 | 0.085 | Heat shock protein 90 beta antagonist | | |
| 0.086 | 0.018 | 0.086 | Exportin-1 inhibitor | | |
| 0.097 | 0.031 | 0.097 | Opioid delta receptor antagonist | | |
| 0.079 | 0.013 | 0.079 | Lysine-specific demethylase 1A inhibitor | | |
| 0.075 | 0.009 | 0.075 | Pregnane X receptor antagonist | | |
| 0.076 | 0.01 | 0.076 | Glucose-6-phosphate isomerase inhibitor | | |
| 0.085 | 0.02 | 0.085 | Acyl-CoA dehydrogenase inhibitor | | |
| 0.114 | 0.049 | 0.114 | Gastric antisecretory | | |
| 0.214 | 0.15 | 0.214 | Thyroid hormone antagonist | | |
| 0.078 | 0.014 | 0.078 | Topoisomerase II beta inhibitor | | |
| 0.106 | 0.043 | 0.106 | Opioid antagonist | | |
| 0.082 | 0.019 | 0.082 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | | |
| 0.141 | 0.079 | 0.141 | Neuropeptide Y1 antagonist | | |
| 0.085 | 0.024 | 0.085 | Beta adrenoreceptor antagonist | | |
| 0.085 | 0.025 | 0.085 | NMDA receptor glycine site agonist | | |
| 0.078 | 0.018 | 0.078 | Botulinum neurotoxin type A inhibitor | | |
| 0.14 | 0.08 | 0.14 | Thiol protease inhibitor | | |
| 0.07 | 0.011 | 0.07 | Factor III inhibitor | | |
| 0.098 | 0.038 | 0.098 | Adrenaline agonist | | |
| 0.097 | 0.037 | 0.097 | CYP2A6 inhibitor | | |
| 0.064 | 0.005 | 0.064 | Kainate receptor agonist | | |
| 0.064 | 0.005 | 0.064 | ATP citrate lysase inhibitor | | |
| 0.091 | 0.033 | 0.091 | Lipase inhibitor | | |
| 0.083 | 0.025 | 0.083 | Protease 3C (Human rhinovirus) inhibitor | | |
| 0.073 | 0.015 | 0.073 | Beta 2 adrenoreceptor agonist | | |
| 0.064 | 0.005 | 0.064 | Estradiol 17 beta-dehydrogenase 1 inhibitor | | |
| 0.063 | 0.005 | 0.063 | Leukotriene C4 antagonist | | |
| 0.117 | 0.059 | 0.117 | Nav1.5 sodium channel blocker | | |
| 0.072 | 0.015 | 0.072 | Ryanodine receptor antagonist | | |
| 0.141 | 0.084 | 0.141 | Insulin secretagoues | | |
| 0.081 | 0.025 | 0.081 | Neuraminidase inhibitor | | |
| 0.183 | 0.127 | 0.183 | MAP-kinase-activated kinase 5 inhibitor | | |
| 0.064 | 0.007 | 0.064 | Estradiol 17 beta-dehydrogenase 3 inhibitor | | |
| 0.081 | 0.025 | 0.081 | Argininosuccinate synthase inhibitor | | |
| 0.164 | 0.108 | 0.164 | MAP kinase kinase 2 inhibitor | | |
| 0.09 | 0.035 | 0.09 | Purinergic P2X2 antagonist | | |
| 0.084 | 0.029 | 0.084 | S-adenosyl-L-methionine decarboxylase inhibitor | | |
| 0.14 | 0.085 | 0.14 | Acetylcholine M1 receptor antagonist | | |
| 0.085 | 0.03 | 0.085 | Dopamine D1 antagonist | | |
| 0.082 | 0.028 | 0.082 | Protein kinase C beta inhibitor | | |
| 0.082 | 0.028 | 0.082 | NMDA receptor agonist | | |
| 0.075 | 0.022 | 0.075 | NMDA 2A receptor antagonist | | |
| 0.079 | 0.026 | 0.079 | Glutamate (mGluR6) antagonist | | |
| 0.062 | 0.01 | 0.062 | Guanylate cyclase inhibitor | | |
| 0.097 | 0.045 | 0.097 | Interleukin 5 antagonist | | |
| 0.075 | 0.025 | 0.075 | Transcription factor AP-1 inhibitor | | |
| 0.084 | 0.034 | 0.084 | Amidase inhibitor | | |
| 0.094 | 0.044 | 0.094 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | | |
| 0.067 | 0.017 | 0.067 | NMDA receptor subunit 3B antagonist | | |
| 0.065 | 0.015 | 0.065 | NMDA receptor subunit 3A antagonist | | |
| 0.068 | 0.018 | 0.068 | Beta 2 adrenoreceptor antagonist | | |
| 0.097 | 0.048 | 0.097 | Histamine N-methyltransferase inhibitor | | |
| 0.06 | 0.011 | 0.06 | Alpha 1d adrenoreceptor agonist | | |
| 0.072 | 0.024 | 0.072 | Beta 1 adrenoreceptor antagonist | | |
| 0.075 | 0.027 | 0.075 | Androgen agonist | | |
| 0.081 | 0.033 | 0.081 | Peroxisome proliferator-activated receptor gamma antagonist | | |
| 0.073 | 0.025 | 0.073 | Histone deacetylase SIRT3 inhibitor | | |
| 0.06 | 0.013 | 0.06 | Liver X receptor alpha agonist | | |
| 0.062 | 0.015 | 0.062 | Dihydroorotase inhibitor | | |
| 0.064 | 0.018 | 0.064 | Heparanase inhibitor | | |
| 0.049 | 0.004 | 0.049 | Estrogen-related receptor gamma antagonist | | |
| 0.09 | 0.046 | 0.09 | Opioid kappa receptor antagonist | | |
| 0.199 | 0.155 | 0.199 | Thyroid hormone beta antagonist | | |
| 0.051 | 0.008 | 0.051 | Vanilloid 3 antagonist | | |
| 0.056 | 0.012 | 0.056 | GABA uptake inhibitor | | |
| 0.082 | 0.039 | 0.082 | Peroxisome proliferator-activated receptor gamma agonist | | |
| 0.053 | 0.01 | 0.053 | Glutamate (mGluR4) agonist | | |
| 0.102 | 0.06 | 0.102 | Butyrylcholinesterase inhibitor | | |
| 0.092 | 0.049 | 0.092 | Bcr-Abl kinase inhibitor | | |
| 0.1 | 0.059 | 0.1 | Glutamate (mGluR7) agonist | | |
| 0.053 | 0.012 | 0.053 | Retinoic acid alpha receptor agonist | | |
| 0.064 | 0.022 | 0.064 | Alpha-mannosidase inhibitor | | |
| 0.073 | 0.032 | 0.073 | MDM2 inhibitor | | |
| 0.08 | 0.04 | 0.08 | Opioid mu receptor antagonist | | |
| 0.051 | 0.011 | 0.051 | Glutamate (mGluR8) agonist | | |
| 0.049 | 0.009 | 0.049 | Uridine phosphorylase inhibitor | | |
| 0.049 | 0.009 | 0.049 | CF transmembrane conductance regulator antagonist | | |
| 0.06 | 0.021 | 0.06 | CD45 antagonist | | |
| 0.058 | 0.019 | 0.058 | Oxytocin agonist | | |
| 0.077 | 0.039 | 0.077 | Phospholipase D inhibitor | | |
| 0.053 | 0.015 | 0.053 | Dihydropteroate synthase inhibitor | | |
| 0.047 | 0.009 | 0.047 | Tubulin agonist | | |
| 0.097 | 0.06 | 0.097 | MAP kinase kinase 1 inhibitor | | |
| 0.051 | 0.014 | 0.051 | Farnesoid X receptor agonist | | |
| 0.053 | 0.017 | 0.053 | Retinoid X receptor agonist | | |
| 0.141 | 0.104 | 0.141 | Interleukin 6 antagonist | | |
| 0.042 | 0.008 | 0.042 | Glutamate (mGluR3) agonist | | |
| 0.042 | 0.008 | 0.042 | Sodium/glucose cotransporter 2 inhibitor | | |
| 0.053 | 0.019 | 0.053 | Kainate receptor antagonist | | |
| 0.067 | 0.033 | 0.067 | Cyclin D1 inhibitor | | |
| 0.058 | 0.025 | 0.058 | Vanilloid 2 antagonist | | |
| 0.152 | 0.119 | 0.152 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | | |
| 0.047 | 0.015 | 0.047 | Retinoid X receptor antagonist | | |
| 0.043 | 0.011 | 0.043 | Liver X receptor beta antagonist | | |
| 0.104 | 0.073 | 0.104 | Electron transport complex I inhibitor | | |
| 0.055 | 0.024 | 0.055 | Potassium channel Kv1.3 blocker | | |
| 0.057 | 0.026 | 0.057 | Lysophosphatidic acid 3 receptor antagonist | | |
| 0.098 | 0.068 | 0.098 | Nav1.1 sodium channel blocker | | |
| 0.066 | 0.036 | 0.066 | Prostaglandin EP2 antagonist | | |
| 0.083 | 0.053 | 0.083 | Glycine receptor antagonist | | |
| 0.037 | 0.007 | 0.037 | Thyroid hormone agonist | | |
| 0.053 | 0.023 | 0.053 | Mannosidase inhibitor | | |
| 0.052 | 0.023 | 0.052 | Fructose-1,6-bisphosphatase inhibitor | | |
| 0.035 | 0.005 | 0.035 | Vanilloid 2 agonist | | |
| 0.088 | 0.059 | 0.088 | ATPase (Vacuolar H+) inhibitor | | |
| 0.048 | 0.019 | 0.048 | Sphingosine kinase 1 inhibitor | | |
| 0.059 | 0.03 | 0.059 | Adenine nucleotide translocase inhibitor | | |
| 0.057 | 0.028 | 0.057 | Prolyl endopeptidase inhibitor | | |
| 0.035 | 0.007 | 0.035 | Prostaglandin F2 alpha agonist | | |
| 0.045 | 0.017 | 0.045 | Retinoid X alpha receptor agonist | | |
| 0.034 | 0.007 | 0.034 | Leukotriene B4 receptor 2 antagonist | | |
| 0.056 | 0.028 | 0.056 | Peroxisome proliferator-activated receptor alpha agonist | | |
| 0.039 | 0.012 | 0.039 | Leukotriene B4 receptor 1 antagonist | | |
| 0.044 | 0.016 | 0.044 | Fumarate hydratase inhibitor | | |
| 0.038 | 0.01 | 0.038 | Liver X receptor alpha antagonist | | |
| 0.085 | 0.058 | 0.085 | mTOR complex 2 inhibitor | | |
| 0.04 | 0.014 | 0.04 | Prostaglandin agonist | | |
| 0.035 | 0.008 | 0.035 | Sodium/glucose cotransporter inhibitor | | |
| 0.054 | 0.028 | 0.054 | Glycine transporter 2 inhibitor | | |
| 0.048 | 0.023 | 0.048 | Beta adrenoreceptor agonist | | |
| 0.044 | 0.019 | 0.044 | Kainate receptor 2 antagonist | | |
| 0.046 | 0.021 | 0.046 | Heme oxygenase inhibitor | | |
| 0.057 | 0.032 | 0.057 | Immunoglobulin Fc receptor antagonist | | |
| 0.061 | 0.037 | 0.061 | Sphingosine 1-phosphate receptor 3 antagonist | | |
| 0.03 | 0.006 | 0.03 | Retinoic acid gamma receptor agonist | | |
| 0.031 | 0.008 | 0.031 | Glutamate (mGluR1a) agonist | | |
| 0.057 | 0.034 | 0.057 | Epithelial sodium channel blocker | | |
| 0.033 | 0.01 | 0.033 | Nicotinic acid receptor 2 antagonist | | |
| 0.047 | 0.024 | 0.047 | Dihydrofolate reductase inhibitor | | |
| 0.13 | 0.107 | 0.13 | Growth hormone agonist | | |
| 0.027 | 0.005 | 0.027 | Estrogen-related receptor gamma agonist | | |
| 0.033 | 0.011 | 0.033 | Prostaglandin EP2 agonist | | |
| 0.029 | 0.007 | 0.029 | Vitamin D receptor antagonist | | |
| 0.049 | 0.027 | 0.049 | Purinergic P2X4 antagonist | | |
| 0.04 | 0.018 | 0.04 | RNA-directed RNA polymerase inhibitor | | |
| 0.038 | 0.017 | 0.038 | Retinoid X alpha receptor antagonist | | |
| 0.047 | 0.026 | 0.047 | Geranyltranstransferase inhibitor | | |
| 0.064 | 0.043 | 0.064 | Calcium channel P-type blocker | | |
| 0.039 | 0.018 | 0.039 | Ceramide glucosyltransferase inhibitor | | |
| 0.067 | 0.047 | 0.067 | Neuronal nicotinic receptor antagonist | | |
| 0.037 | 0.017 | 0.037 | Liver X receptor beta agonist | | |
| 0.025 | 0.005 | 0.025 | Nicotinic acid receptor 1 antagonist | | |
| 0.04 | 0.021 | 0.04 | Nicotinic acid receptor agonist | | |
| 0.049 | 0.03 | 0.049 | Opioid mu receptor agonist | | |
| 0.113 | 0.094 | 0.113 | Toll-Like receptor 9 antagonist | | |
| 0.074 | 0.055 | 0.074 | Vanilloid 4 agonist | | |
| 0.071 | 0.052 | 0.071 | Cathepsin G inhibitor | | |
| 0.029 | 0.01 | 0.029 | Retinoic acid receptor agonist | | |
| 0.072 | 0.054 | 0.072 | Adenosine A3 receptor antagonist | | |
| 0.035 | 0.017 | 0.035 | Liver X receptor antagonist | | |
| 0.05 | 0.032 | 0.05 | Plasminogen activator inhibitor antagonist | | |
| 0.05 | 0.033 | 0.05 | Bombesin 2 receptor antagonist | | |
| 0.035 | 0.018 | 0.035 | HCV NS5B polymerase inhibitor | | |
| 0.027 | 0.01 | 0.027 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | | |
| 0.039 | 0.022 | 0.039 | Glutamate (mGluR3) antagonist | | |
| 0.028 | 0.012 | 0.028 | Prostaglandin E2 agonist | | |
| 0.024 | 0.008 | 0.024 | Retinoid X beta receptor antagonist | | |
| 0.026 | 0.01 | 0.026 | ICAM 1 antagonist | | |
| 0.039 | 0.023 | 0.039 | Arginase inhibitor | | |
| 0.073 | 0.057 | 0.073 | Analgesic, opioid | | |
| 0.07 | 0.055 | 0.07 | Metalloproteinase-9 inhibitor | | |
| 0.075 | 0.06 | 0.075 | Acetylcholine nicotinic antagonist | | |
| 0.074 | 0.059 | 0.074 | Sphingosine 1-phosphate receptor antagonist | | |
| 0.024 | 0.01 | 0.024 | Retinoic acid alpha receptor antagonist | | |
| 0.068 | 0.053 | 0.068 | Secretase beta inhibitor | | |
| 0.022 | 0.008 | 0.022 | Antibiotic Anthracycline-like | | |
| 0.075 | 0.061 | 0.075 | Antineoplastic antibiotic | | |
| 0.023 | 0.01 | 0.023 | Neuraminidase (Influenza B) inhibitor | | |
| 0.036 | 0.023 | 0.036 | Phosphoglycerate kinase inhibitor | | |
| 0.029 | 0.016 | 0.029 | Hedgehog signaling activator | | |
| 0.039 | 0.027 | 0.039 | Histone deacetylase 9 inhibitor | | |
| 0.071 | 0.059 | 0.071 | Phosphodiesterase VI inhibitor | | |
| 0.03 | 0.017 | 0.03 | Purinergic P2Y15 antagonist | | |
| 0.025 | 0.013 | 0.025 | Fructose-1,6-bisphosphatase 1 inhibitor | | |
| 0.017 | 0.005 | 0.017 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | | |
| 0.116 | 0.104 | 0.116 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | | |
| 0.02 | 0.009 | 0.02 | Alpha 2a adrenoreceptor agonist | | |
| 0.131 | 0.12 | 0.131 | LIM domain kinase 1 inhibitor | | |
| 0.035 | 0.023 | 0.035 | HMG CoA reductase inhibitor | | |
| 0.034 | 0.023 | 0.034 | Free fatty acid receptor 1 antagonist | | |
| 0.05 | 0.039 | 0.05 | Ornithine carbamoyltransferase inhibitor | | |
| 0.077 | 0.067 | 0.077 | Calcium antagonist | | |
| 0.025 | 0.015 | 0.025 | Glutamate (mGluR1) agonist | | |
| 0.138 | 0.128 | 0.138 | Cyclin-dependent kinase 3 inhibitor | | |
| 0.026 | 0.017 | 0.026 | Prostaglandin H2 antagonist | | |
| 0.052 | 0.043 | 0.052 | Thromboxane synthase inhibitor | | |
| 0.019 | 0.009 | 0.019 | Telomerase stimulant | | |
| 0.014 | 0.005 | 0.014 | Thromboxane agonist | | |
| 0.02 | 0.011 | 0.02 | Retinoic acid receptor antagonist | | |
| 0.109 | 0.101 | 0.109 | Cytokine production inhibitor | | |
| 0.036 | 0.027 | 0.036 | 5-Alpha-reductase inhibitor | | |
| 0.034 | 0.026 | 0.034 | Opioid delta receptor agonist | | |
| 0.039 | 0.031 | 0.039 | Histone deacetylase 8 inhibitor | | |
| 0.025 | 0.018 | 0.025 | Complement factor 1s inhibitor | | |
| 0.032 | 0.025 | 0.032 | Protein kinase (CK2) beta inhibitor | | |
| 0.043 | 0.037 | 0.043 | Parathyroid hormone antagonist | | |
| 0.022 | 0.015 | 0.022 | Protease (Human cytomegalovirus) inhibitor | | |
| 0.041 | 0.035 | 0.041 | AICAR transformylase inhibitor | | |
| 0.048 | 0.042 | 0.048 | CXC chemokine 1 receptor antagonist | | |
| 0.016 | 0.01 | 0.016 | Thromboxane A2 agonist | | |
| 0.016 | 0.01 | 0.016 | Purinergic P2Y1 agonist | | |
| 0.037 | 0.031 | 0.037 | Membrane dipeptidase inhibitor | | |
| 0.07 | 0.065 | 0.07 | Metalloproteinase-2 inhibitor | | |
| 0.013 | 0.007 | 0.013 | Glutamate (mGluR6) agonist | | |
| 0.02 | 0.014 | 0.02 | Retinoic acid beta receptor agonist | | |
| 0.052 | 0.047 | 0.052 | Adenosine A1 receptor antagonist | | |
| 0.041 | 0.036 | 0.041 | Phosphorylase inhibitor | | |
| 0.027 | 0.023 | 0.027 | Nicotinic alpha4beta2 receptor agonist | | |
| 0.051 | 0.047 | 0.051 | Glucosylceramidase inhibitor | | |
| 0.022 | 0.018 | 0.022 | Dopamine D1 agonist | | |
| 0.049 | 0.046 | 0.049 | Nicotinic alpha3beta2 receptor antagonist | | |
| 0.042 | 0.039 | 0.042 | Adenosine deaminase inhibitor | | |
| 0.016 | 0.013 | 0.016 | Vitamin D receptor agonist | | |
| 0.026 | 0.023 | 0.026 | CDK4/cyclin D3 inhibitor | | |
| 0.019 | 0.016 | 0.019 | Imidazoline I1 receptor antagonist | | |
| 0.046 | 0.044 | 0.046 | Opioid agonist | | |
| 0.008 | 0.007 | 0.008 | Thyroid hormone beta agonist | | |
| 0.021 | 0.019 | 0.021 | Beta 1 adrenoreceptor agonist | | |
| 0.021 | 0.019 | 0.021 | Isoleucine-tRNA ligase inhibitor | | |
| 0.011 | 0.009 | 0.011 | Retinoic acid receptor gamma antagonist | | |
| 0.028 | 0.026 | 0.028 | Lysophosphatidic acid 2 receptor antagonist | | |
| 0.014 | 0.013 | 0.014 | Thyroid hormone alpha antagonist | | |
| 0.053 | 0.052 | 0.053 | Adenosine A2a receptor antagonist | | |
| 0.052 | 0.051 | 0.052 | Acetylcholine M3 receptor antagonist | | |
| 0.025 | 0.024 | 0.025 | Thymidine kinase (Herpes simplex virus 1) inhibitor | | |